» Articles » PMID: 17635181

Genetic Polymorphisms of Drug-metabolizing Enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek Population

Overview
Specialty Pharmacology
Date 2007 Jul 20
PMID 17635181
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to determine the prevalence of the most common allelic variants of the polymorphic cytochrome P450 (CYP) enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 and to predict the genotype frequency for each polymorphism in the Greek population. DNA isolated from peripheral blood samples derived from 283 non-related Greek ethnic subjects was used to determine the frequency of CYP2D6*3, CYP2D6*4, CYP2C9*2, CYP2C9*3 and CYP3A5*3 allelic variants by the polymerase chain reaction (PCR)-restriction fragment length polymorphism method, CYP2C19*2 and CYP2C19*3 with allelic specific amplification (PCR-ASA), and CYP2D6*2 (gene duplications) by long PCR analysis. The allelic frequencies (out of a total of 566 alleles) for CYP2D6*3 and CYP2D6*4, were 2.3% and 17.8%, respectively, while gene duplications (CYP2D6*2) were found in 7.4% of the subjects tested. For CYP2C9*2 and CYP2C9*3 polymorphisms the allelic frequencies were 12.9% and 8.13% respectively. For CYP2C19, the *2 polymorphism was present at an allelic frequency of 13.1%, while no subjects were found carrying the CYP2C19*3 allele. Finally, the CYP3A5*3 allele was abundantly present in the Greek population with an allelic frequency of 94.4%. Overall our results show that the frequencies of the common defective allelic variants of CYP2C9, CYP2C19 and CYP3A5 in Greek subjects are similar to those reported for several other Caucasian populations. Finally, a high prevalence of CYP2D6 gene duplication among Greeks was found, a finding that strengthens the idea that a South/North gradient exists in the occurrence of CYP2D6 ultrarapid metabolizers in European populations.

Citing Articles

Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation.

Ragia G, Pallikarou M, Manolopoulou Y, Vorvolakos T, Manolopoulos V Pharmacogenomics. 2024; 25(5-6):217-229.

PMID: 38884939 PMC: 11388136. DOI: 10.1080/14622416.2024.2346072.


Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach.

Alonso Llorente A, Salgado Garrido J, Teijido Hermida O, Gonzalez Andrade F, Valiente Martin A, Fanlo Villacampa A Heliyon. 2024; 10(7):e28566.

PMID: 38586400 PMC: 10998100. DOI: 10.1016/j.heliyon.2024.e28566.


Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for Eradication in High Clarithromycin Resistance Areas.

Georgopoulos S, Xirouchakis E, Liatsos C, Apostolopoulos P, Kasapidis P, Martinez-Gonzalez B Antibiotics (Basel). 2024; 13(3).

PMID: 38534715 PMC: 10967285. DOI: 10.3390/antibiotics13030280.


*2/*2 Genotype is a Risk Factor for Multi-Site Arteriosclerosis: A Hospital-Based Cohort Study.

Xie J, Pan T, Luo W, Zhang S, Fang Y, Xu Z Int J Gen Med. 2023; 16:5139-5146.

PMID: 37954650 PMC: 10637229. DOI: 10.2147/IJGM.S437251.


Differences in the Proportion of CYP2C19 Loss-of-Function Between Cerebral Infarction and Coronary Artery Disease Patients.

Shi Y, Yang Y, Feng M, Ling W, Wei T, Cao Y Int J Gen Med. 2023; 16:3473-3481.

PMID: 37601806 PMC: 10438470. DOI: 10.2147/IJGM.S420108.